Business Wire

PA-TRINSEO

19.5.2023 19:24:35 CEST | Business Wire | Press release

Share
Trinseo Starts Up Polycarbonate Dissolution Pilot Facility in the Netherlands

Trinseo (NYSE: TSE), a specialty material solutions provider, announced today the inauguration of its polycarbonate (PC) dissolution pilot facility in Terneuzen, the Netherlands on April 5, 2023. The new pilot facility is a major step in Trinseo’s commitment to sustainability, part of the journey in realizing the company’s sustainability goals. The guests of honor at the inauguration ceremony included Jo-Annes de Bat, Provincial Executive (responsible for regional economy) of the Netherlands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005469/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Trinseo is excited to announce the inauguration of our polycarbonate (PC) dissolution pilot plant in Terneuzen, the Netherlands. This technology allows us to extract 100% recycled PC for use in new materials. (Photo: Business Wire)

An essential element of Trinseo’s innovation is focused on developing and delivering sustainable solutions. Across all businesses, this is a driving force behind our R&D efforts. While we are currently in the R&D phase, the state-of-the-art pilot facility is situated in a temporary area in Trinseo’s Terneuzen site and will later be moved into the Central Process Research Laboratory in the same site, which is currently under construction.

“Dissolution recycling” is a type of physical recycling process where the needed polymer is extracted by the use of solvents. The extracted polymers will then be used to make new recycled polymers. Trinseo’s PC dissolution technology is an advanced technology by which post- or pre-consumer materials containing PC, be it an automotive or consumer electronics part that is mixed with other plastics, metal or even glass, can be put directly into the solvent without any pre-treatment. The solvent will dissolve PC contained in those end-of-life parts while all other non-PC materials will remain, and can then be used for other recycling purposes. The dissolved PC extracted is 100% recycled PC that could be used for compounding into new materials for an array of applications, such as mobile phone casing, printer enclosure or automotive parts.

“We are very excited to have started up the pilot facility for PC dissolution,” said Francesca Reverberi, Senior Vice President & Chief Sustainability Officer at Trinseo, “This technology deepens the potential in circularity.”

“This is a R&D milestone in Trinseo’s sustainability journey,” added Han Hendriks, Senior Vice President, Chief Technology Officer. “With our expanding R&D capabilities and organization, more robust innovations are in the pipeline.”

The pilot plant will play a significant role in helping Trinseo achieve its 2030 Sustainability Goals, while accelerating recycling and increasing the supply of sustainable feedstock.

About Trinseo

Trinseo (NYSE: TSE), a specialty material solutions provider, partners with companies to bring ideas to life in an imaginative, smart and sustainably focused manner by combining its premier expertise, forward-looking innovations and best-in-class materials to unlock value for companies and consumers.

From design to manufacturing, Trinseo taps into decades of experience in diverse material solutions to address customers’ unique challenges in a wide range of industries, including building and construction, consumer goods, medical and mobility.

Trinseo’s approximately 3,400 employees bring endless creativity to reimagining the possibilities with clients all over the world from the company’s locations in North America, Europe and Asia Pacific. Trinseo reported net sales of approximately $5.0 billion in 2022. Discover more by visiting www.trinseo.com and connecting with Trinseo on LinkedIn, Twitter, Facebook and WeChat.

Cautionary Note on Forward-Looking Statements

This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, forecasts, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," “believe,” "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, our ability to successfully investigate and remediate chemical releases on or from our sites, make related capital expenditures, reimburse third-party cleanup costs or settle potential regulatory penalties or other claims; our ability to successfully execute our business and transformation strategy; increased costs or disruption in the supply of raw materials; increased energy costs; our ability to successfully generate cost savings and increase profitability through asset restructuring initiatives; compliance with laws and regulations impacting our business; conditions in the global economy and capital markets; and those discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results, performance or achievements may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005469/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 16:05:00 CEST | Press release

Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive

Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 15:00:00 CEST | Press release

Partnership brings together Resurgens' software investing expertise and Qarma’s leading quality and compliance platform to accelerate product innovation and expand its reach across North America, Europe, and Asia Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma ha

Tecnotree Signs 17.5 Million USD Multi-Year Agreement with Existing Communications Service Provider in the Americas13.8.2026 14:04:00 CEST | Press release

Tecnotree, a global provider of 5g and AI-native digital business support systems (BSS) and digital transformation solutions for communications service providers, announced the signing of a new multi-year, multi-region agreement with an existing communications service provider in the Americas. The agreement reflects Tecnotree’s continued focus on expanding long-term customer relationships through its 5g AI-native digital platforms and services enabling communications service providers to modernize business operations, accelerate service innovation, and enhance customer experiences, Tecnotree continues to support the evolving digital transformation priorities of operators worldwide. “The Americas remains an important market for Tecnotree, where the company continues to support communications service providers with solutions that simplify operations, enable business agility, and create sustainable value through next-generation digital services,” said Padma Ravichander, CEO Tecnotree. Abo

Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 14:00:00 CEST | Press release

Deployment will add high-density NVIDIA-powered AI capacity at Vantage’s Newport campus, supporting the UK’s ambition to scale domestic AI compute and reinforcing South Wales as a strategic digital infrastructure hub Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterpr

SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 12:30:00 CEST | Press release

Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA1 Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Successful Fee Increases, Positioning the Business for Accelerated Network Expansion SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye